D57.433
Sickle-cell thalassemia beta zero with cerebral vascular involvement
Clinical Classification Guidelines
Inclusion Terms
- HbS-beta zero with cerebral vascular involvement
- Sickle-cell beta zero with cerebral vascular involvement
Code Also
- , if applicable cerebral infarction (I63.-)
Medical Intelligence & Overview
Sickle-cell thalassemia beta zero with cerebral vascular involvement is a complex inherited blood disorder that affects the shape and functioning of red blood cells. This condition combines characteristics of sickle-cell disease and thalassemia, leading to significant health challenges, especially related to blood flow in the brain. It is classified under ICD-10 as D57.433, highlighting its specific nature and complications involving brain vasculature.
Causes & Symptoms
Clinical Causes: Genetic inheritance: The condition is inherited from parents passing on sickle-cell and beta-zero thalassemia gene mutations. Mutations affecting hemoglobin production: Abnormal hemoglobin S (sickle hemoglobin) and reduced or absent beta-globin chains lead to defective red blood cells. Combination of sickle-cell trait and thalassemia genes: The coexistence of these genetic factors results in more severe disease manifestation.
Key Symptoms: Signs of vaso-occlusion, such as pain crises, especially in the chest, joints, or abdomen. Neurological symptoms including headaches, dizziness, or stroke-like episodes due to cerebral vessel blockage. Chronic anemia resulting in fatigue and weakness. Delayed growth and development in children. Increased risk of infections because of spleen damage. Potential seizures or neurological deficits if brain injury occurs.
Diagnostic & Treatment
Diagnosis Path: Diagnosis is primarily through blood tests that identify abnormal hemoglobin, such as hemoglobin electrophoresis. Imaging tests like MRI or CT scans may be used to detect cerebral vascular involvement. A detailed clinical history and physical examination assist in assessing neurological signs and symptoms. Genetic testing can confirm the presence of sickle-cell and beta-zero thalassemia mutations.
Treatment Protocols: While there is no universal cure, management focuses on alleviating symptoms and preventing complications. Treatments may include:
Clinical Advice & FAQs
Billing Guidance
Is D57.433 a billable ICD-10 code?
Yes, D57.433 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.433?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta zero with cerebral vascular involvement and any associated comorbidities for accurate reporting.
Cite this Clinical Reference